June 12, 2018

Growth of the IL-17 inhibitors and Tremfya has been at the expense of the established TNF inhibitors and Janssen’s own Stelara.

US Dermatologists Report Significant Growth of Next-Generation Psoriasis Biologics–Novartis’ Cosentyx, Eli Lilly’s Taltz, and Janssen’s Tremfya